UNSPSC 51312703: Pyrrobutamine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C20H22ClN, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VE6KP18S8X, chemically known as pyrrolidine, 1-(4-(4-chlorophenyl)-3-phenyl-2-butenyl)- but generally known as pyrrobutamine, which bears US NIH Compound Identifier 5284614. European Medicines Agency schedules Pyrrobutamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15066MIG.

World Health Organization schedules pyrrobutamine in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, PYRROBUTAMINE remains the US FDA Preferred Term for this commodity. Pyrrobutamine bears US NLM identifiers UMLS ID C0163091 and NCI Concept Code C81146. SMILES: CLC1CCC(C/C(=C\CN2CCCC2)C2CCCCC2)CC1.

UNSPSC 51312703 Pyrrobutamine, a Commodity code, does not align with the recent state and local opportunities posted under this classification. The three most recent solicitations involve naloxone and drug deactivation systems, direct-to-manufacturer pharmacy programs, and generic multi-source pharmaceuticals and OTC products — none of which center on pyrrobutamine as a primary procurement focus. The code shows little relevant recent activity tied to its nominal scope, and the mismatch between the code taxonomy and actual buying patterns suggests this Commodity code may be misapplied or receives minimal state and local procurement demand.

The issuing bodies in the posted opportunities span county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance administering on behalf of member state and local jurisdictions including Oregon). The Seminole County IFB for naloxone and drug deactivation systems closed July 26, 2023, with quarterly deliveries required; the Texas HHS RFI on direct-to-manufacturer prescriptions was released April 3, 2026, as exploratory market intelligence; and the Minnesota MMCAP RFP for generic pharmaceuticals and OTC products had a proposal deadline of March 26, 2026, with contract effectiveness set for July 1, 2026. Geographic activity is concentrated in Florida, Texas, and Minnesota, with broader multistate participation under MMCAP's cooperative framework. The mismatch between this Commodity code and the posted solicitations suggests that firms pursuing state and local pharmaceutical procurement should monitor higher-level UNSPSC Family or Class codes that encompass pharmaceutical products more broadly rather than relying on this specific code for market intelligence.